Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. GOOGL
5. MU
6. DFTX
7. USO
8. APGE
9. ABBV
10. NAVN

Go back to Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr
Gilead Sciences (NASDAQ: GILD) Delayed: 124.87 --0 (-0%)
Previous Close $124.87    52 Week High $108.63 
Open $124.87    52 Week Low $71.39 
Day High $124.87    P/E 68.99 
Day Low $124.87    EPS $1.81 
Volume 7,030       

Merck & Co. (NYSE: MRK) Delayed: 115.48 --0 (-0%)
Previous Close $115.48    52 Week High $65.46 
Open $115.48    52 Week Low $47.97 
Day High $115.48    P/E 78.56 
Day Low $115.48    EPS $1.47 
Volume 5,368